Extended adjuvant aromatase inhibition after sequential endocrine therapy in postmenopausal women with breast cancer: follow-up analysis of the randomised phase 3 DATA trial
-
Published:2023-04
Issue:
Volume:58
Page:101901
-
ISSN:2589-5370
-
Container-title:eClinicalMedicine
-
language:en
-
Short-container-title:eClinicalMedicine
Author:
Tjan-Heijnen Vivianne C.G.,
Lammers Senna W.M.ORCID,
Geurts Sandra M.E.ORCID,
Vriens Ingeborg J.H.,
Swinkels Astrid C.P.ORCID,
Smorenburg Carolien H.,
van der Sangen Maurice J.C.ORCID,
Kroep Judith R.,
de Graaf Hiltje,
Honkoop Aafke H.,
Erdkamp Frans L.G.,
de Roos Wilfred K.,
Linn Sabine C.,
Imholz Alexander L.T.
Reference28 articles.
1. Breast cancer statistics, 2019;DeSantis;CA Cancer J Clin,2019
2. Comprehensive trends in incidence, treatment, survival and mortality of first primary invasive breast cancer stratified by age, stage and receptor subtype in The Netherlands between 1989 and 2017;van der Meer;Int J Cancer,2021
3. 20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years;Pan;N Engl J Med,2017
4. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial;Davies;Lancet,2013
5. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17;Goss;J Natl Cancer Inst,2005
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献